RU2345072C1 - N-(1,3-tiazol-2-yl)amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexane acid, demonstrating anti-inflammatory and analgetic activity and method of obtaining - Google Patents
N-(1,3-tiazol-2-yl)amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexane acid, demonstrating anti-inflammatory and analgetic activity and method of obtaining Download PDFInfo
- Publication number
- RU2345072C1 RU2345072C1 RU2007128279/04A RU2007128279A RU2345072C1 RU 2345072 C1 RU2345072 C1 RU 2345072C1 RU 2007128279/04 A RU2007128279/04 A RU 2007128279/04A RU 2007128279 A RU2007128279 A RU 2007128279A RU 2345072 C1 RU2345072 C1 RU 2345072C1
- Authority
- RU
- Russia
- Prior art keywords
- inflammatory
- dimethyl
- diphenylmethylenehydrazono
- amides
- obtaining
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 title claims abstract description 9
- 230000000202 analgesic effect Effects 0.000 title abstract description 6
- 239000002253 acid Substances 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 title abstract 2
- CSDGAIQEYSKWTL-UHFFFAOYSA-N 1-(benzhydrylidenehydrazinylidene)-5,5-dimethylhexane-2,4-dione Chemical compound C1(=CC=CC=C1)C(=NN=CC(CC(C(C)(C)C)=O)=O)C1=CC=CC=C1 CSDGAIQEYSKWTL-UHFFFAOYSA-N 0.000 title 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 claims description 9
- -1 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexanoic acid Chemical compound 0.000 claims description 7
- 230000001760 anti-analgesic effect Effects 0.000 claims description 4
- PYSJLPAOBIGQPK-UHFFFAOYSA-N 4-phenyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1 PYSJLPAOBIGQPK-UHFFFAOYSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 18
- 239000000126 substance Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 4
- 229940063674 voltaren Drugs 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000002322 anti-exudative effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- YTSZIESHCFAFLD-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxohexanoic acid Chemical compound CC(C)(C)C(=O)CC(=O)C(O)=O YTSZIESHCFAFLD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Изобретение относится к области органической химии, к производным ациклических поликарбонильных соединений, а именно к новым N-(1,3-тиазол-2-ил)амидам 2-дифенилметиленгидразоно-5,5-диметил-2,4-диоксогексановой кислоты формулы (Iа, б):The invention relates to the field of organic chemistry, to derivatives of acyclic polycarbonyl compounds, namely to the new N- (1,3-thiazol-2-yl) amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexanoic acid of the formula (Ia b):
проявляющие противовоспалительную и анальгетическую активность, которые могут найти применение в медицине в качестве лекарственных препаратов. Известен структурный аналог заявляемым соединениям - N-(1,3-тиазол-2-ил)амид 3-гидрокси-5,5-диметил-4-оксо-2-гексеновой кислоты (II), получаемый взаимодействием пивалоилпировиноградной кислоты с 2-аминотиазолом [Березина B.C., Козьминых В.О., Игидов Н.М., Ширинкина С.С, Козьминых Е.Н., Махмудов P.P., Буканова Е.В. Журн. орган. химии. 2001. Т.37. №4. С.574-581]. Синтез структурного аналога осуществляется по следующей схеме:showing anti-inflammatory and analgesic activity, which can be used in medicine as drugs. Known structural analogue of the claimed compounds is N- (1,3-thiazol-2-yl) amide 3-hydroxy-5,5-dimethyl-4-oxo-2-hexenoic acid (II), obtained by the interaction of pivaloylpyruvic acid with 2-aminothiazole [Berezina BC, Kozminykh V.O., Igidov N.M., Shirinkina S.S., Kozminykh E.N., Makhmudov PP, Bukanova E.V. Zhurn. organ. chemistry. 2001.V. 37. Number 4. S.574-581]. The synthesis of the structural analogue is carried out according to the following scheme:
К недостаткам данного способа относится невозможность получения N-(1,3-тиазол-2-ил)амидов 2-дифенилметиленгидразоно-5,5-диметил-2,4-диоксогексановой кислоты.The disadvantages of this method include the impossibility of obtaining N- (1,3-thiazol-2-yl) amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexanoic acid.
Задачей данного изобретения является разработка метода синтеза неописанных ранее N-(1,3-тиазол-2-ил)амидов 2-дифенил-метиленгидразоно-5,5-диметил-2,4-диоксогексановой кислоты (Iа, б), проявляющих более высокое противовоспалительное и анальгетическое действие и обладающих более низкой токсичностью, чем известные лекарственные средства.The objective of the invention is to develop a method for the synthesis of previously undescribed N- (1,3-thiazol-2-yl) amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexanoic acid (Ia, b), showing a higher anti-inflammatory and analgesic effects and having lower toxicity than known drugs.
Поставленная задача осуществляется путем кратковременного нагревания 5-трет-бутил-3-дифенилгидразона-2,3-дигидро-2-фуранона (III) [Васильева Н.Н., Игидов Н.М. Вестник студенческого общества. Пермь, ПГФА. 2006. №1 С.35] с 2-аминотиазолом или 2-амино-4-фенилтиазолом в среде абсолютного толуола по схеме:The task is carried out by short-term heating of 5-tert-butyl-3-diphenylhydrazone-2,3-dihydro-2-furanone (III) [Vasilieva N.N., Igidov N.M. Bulletin of the student society. Perm, PFA. 2006. No. 1 P.35] with 2-aminothiazole or 2-amino-4-phenylthiazole in absolute toluene medium according to the scheme:
Пример получения заявляемого соединения Iа:An example of the preparation of the claimed compound Ia:
К раствору 0,15 г (0,0015 моль) 2-аминотиазола в 10 мл абсолютного толуола добавляют раствор 0,5 г (0,0015 моль) фуранона (III) в 40 мл абсолютного толуола и нагревают в течение 5 минут. Смесь оставляют на сутки. Растворитель испаряют, сухой остаток кристаллизуют из этанола или этилацетата. Получают 0,45 г (69%) бесцветного кристаллического соединения (Iа) с Тпл.=175-176°С. C24H24N4SO2. М.м.=432,55. ИК спектр, v, см-1 (кристаллы): 1708 (С=О), 1610 (C=N). Спектр ПМР, δ, м.д. ДМСО-d6: 1,09 с (9Н, С(СН3)3), 4,07 с (2Н, CH2), 7,16-7,39 м (12Н, 2С6Н5, тиазолил), 11,4 уш. с (1Н, NH).To a solution of 0.15 g (0.0015 mol) of 2-aminothiazole in 10 ml of absolute toluene, a solution of 0.5 g (0.0015 mol) of furanone (III) in 40 ml of absolute toluene is added and heated for 5 minutes. The mixture is left for a day. The solvent is evaporated, the solid residue is crystallized from ethanol or ethyl acetate. Obtain 0.45 g (69%) of a colorless crystalline compound (Ia) with T pl. = 175-176 ° C. C 24 H 24 N 4 SO 2 . M.m. = 432.55. IR spectrum, v, cm -1 (crystals): 1708 (C = O), 1610 (C = N). PMR spectrum, δ, ppm DMSO-d6: 1.09 s (9H, C (CH 3 ) 3 ), 4.07 s (2H, CH 2 ), 7.16-7.39 m (12H, 2C 6 H 5 , thiazolyl), 11 , 4 ears. s (1H, NH).
Пример получения заявляемого соединения 1б:An example of the preparation of the claimed compound 1b:
К раствору 0,26 г (0,0015 моль) 2-амино-4-фенилтиазола в 10 мл абсолютного толуола добавляют раствор 0,5 г (0,0015 моль) фуранона (III) в 40 мл абсолютного толуола и нагревают в течение 5 минут. Смесь оставляют на сутки. Растворитель испаряют, сухой остаток кристаллизуют из этанола. Получают 0,51 г (66%) кристаллического соединения (Iа) желтого цвета с Тпл.=189-190°С. C30H28N4SO2. М.м.=508,63. ИК спектр, v, см-1 (кристаллы): 1710 (С=O), 1618 (C=N). Спектр ПМР, δ, м. д. ДМСО-d6: 1,15 с (9Н, С(СН3)3), 4,18 с (2Н, СН2), 7,04-7,71 м (16Н, 3С6Н5, тиазолил), 9,92 уш. с (1Н, NH).To a solution of 0.26 g (0.0015 mol) of 2-amino-4-phenylthiazole in 10 ml of absolute toluene, a solution of 0.5 g (0.0015 mol) of furanone (III) in 40 ml of absolute toluene is added and heated for 5 minutes. The mixture is left for a day. The solvent is evaporated, the solid residue is crystallized from ethanol. Obtain 0.51 g (66%) of a yellow crystalline compound (Ia) with T pl. = 189-190 ° C. C 30 H 28 N 4 SO 2 . M.m. = 508.63. IR spectrum, v, cm -1 (crystals): 1710 (C = O), 1618 (C = N). 1 H-NMR spectrum, δ, ppm DMSO-d6: 1.15 s (9H, C (CH 3 ) 3 ), 4.18 s (2H, CH 2 ), 7.04-7.71 m (16H, 3C 6 H 5 , thiazolyl), 9.92 br. s (1H, NH).
Полученные соединения (Iа, б) - вещества, растворимые в диметил-сульфоксиде и диметилформамиде, труднорастворимые в спирте и этилацетате, нерастворимые в гексане и воде.The obtained compounds (Ia, b) are substances soluble in dimethyl sulfoxide and dimethylformamide, sparingly soluble in alcohol and ethyl acetate, insoluble in hexane and water.
Исследование противовоспалительной, анальгетической активности и острой токсичности проводили в лаборатории БАВ Естественнонаучного института Пермского государственного университета.The study of anti-inflammatory, analgesic activity and acute toxicity was carried out in the laboratory of the BAS of the Natural Sciences Institute of Perm State University.
Острую токсичность (ЛД50, мг/мл) соединений (Iа, б) определяли по методу Г.Н.Першина [Першин Г.Н. Методы экспериментальной химиотерапии // М., С.100, 109-117 (1971)]. Соединения (Ia, б) вводили внутрибрюшинно белым мышам массой 16-18 г в виде взвеси в 2% крахмальной слизи. Для исследуемых соединений (Iа, б) ЛД50 составляет >1500 мг/кг.Acute toxicity (LD 50 , mg / ml) of compounds (Ia, b) was determined according to the method of G. N. Pershin [Pershin G. N. Methods of experimental chemotherapy // M., S. 100, 109-117 (1971)]. Compounds (Ia, b) were administered intraperitoneally to white mice weighing 16-18 g as a suspension in 2% starch mucus. For the studied compounds (Ia, b), the LD 50 is> 1500 mg / kg.
Согласно классификации токсичности препаратов соединения (Iа, б) относятся к V классу практически нетоксичных препаратов [Измеров Н.Ф., Сапоцкий И.В., Сидоров К.К. Параметры токсикометрии промышленных ядов. - М.: Медицина, 1977. - с.196].According to the classification of toxicity of drugs, compounds (Ia, b) belong to class V of practically non-toxic drugs [Izmerov N.F., Sapotsky IV, Sidorov K.K. Toxicometry parameters of industrial poisons. - M .: Medicine, 1977. - p.196].
Противовоспалительную активность изучали на белых крысах линии Wistar массой 170-200 г. Антиэкссудативное действие соединений (Iа, б) оценивали на модели острого воспалительного отека лапки, вызванного путем субплантарного введения 0,1 мл 1% раствора каррагенина. Показателем действия исследуемых соединений, вводимых внутрь в дозе 50 мг/кг в 2% растворе крахмальной слизи, служила величина отека лапки, определяемая онкометрически. О силе антиэкссудативного действия судили по степени ингибирования воспалительной реакции в % к контролю [Методические рекомендации по экспериментальному доклиническому изучению нестероидных противовоспалительных фармакологических веществ. М. - 1982. - 17 с. Одобрено Фармакологическим комитетом МЗ СССР 11 ноября 1992 г. Протокол №22]. Сравнивали эффект с вольтареном в дозе 10 мг/кг [Неугодова В.П., Цариченко Г.В., Рындина С.Е. Токсикологическая оценка вольтарена // Фармаколог, и токсиколог. - 1986. Т.49. - №1 С.123].Anti-inflammatory activity was studied on white Wistar rats weighing 170-200 g. The antiexudative effect of compounds (Ia, b) was evaluated on the model of acute inflammatory paw edema caused by subplanetary administration of 0.1 ml of 1% carrageenin solution. An indicator of the action of the studied compounds, administered orally at a dose of 50 mg / kg in a 2% starch mucus solution, was the size of the swelling of the paw, determined oncometrically. The strength of the antiexudative effect was judged by the degree of inhibition of the inflammatory reaction in% of control [Methodological recommendations for experimental preclinical study of non-steroidal anti-inflammatory pharmacological substances. M. - 1982. - 17 p. Approved by the Pharmacological Committee of the Ministry of Health of the USSR on November 11, 1992, Protocol No. 22]. The effect was compared with voltaren at a dose of 10 mg / kg [Neugodova V.P., Tsarichenko G.V., Ryndina S.E. Toxicological evaluation of voltaren // Pharmacologist, and toxicologist. - 1986.V.49. - No. 1 P.123].
Анальгетическую активность соединений (Iа, б) изучали на беспородных мышах массой 18-22 г с помощью теста «горячая пластинка» [Radell Z.O., Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. // Arch. Intermat. Pharmacodun. Et ther. 1957. - Vol.11. - №4. - S.409-419].The analgesic activity of compounds (Ia, b) was studied on outbred mice weighing 18-22 g using the hot plate test [Radell Z.O., Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. // Arch. Intermat. Pharmacodun Et ther. 1957. - Vol. 11. - No. 4. - S.409-419].
Исследуемые соединения вводили внутрибрюшинно в виде 2% крахмальной слизи в дозе 50 мг/кг за 0,5 ч до помещения животных на нагретую до 53,5°С металлическую пластинку. Показателем болевой чувствительности служила длительность пребывания животного на горячей пластинке до момента облизывания задних лапок, измеряемая в секундах.The test compounds were administered intraperitoneally in the form of 2% starch mucus at a dose of 50 mg / kg 0.5 h before the animals were placed on a metal plate heated to 53.5 ° C. An indicator of pain sensitivity was the duration of the animal’s stay on the hot plate until the hind legs were licked, measured in seconds.
Результаты испытаний представлены в таблицеThe test results are presented in the table.
р<0,537.00 ± 2.30
p <0.5
р<0,536.20 ± 5.18
p <0.5
Как видно из таблицы, заявляемые соединения (Iа, б) обладают выраженной противовоспалительной и анальгетической активностью, менее токсичны, чем препарат сравнения вольтарен. Следовательно, заявляемые соединения (Iа, б) могут найти применение в медицинской практике в качестве противовоспалительных и анальгетических лекарственных средств.As can be seen from the table, the claimed compounds (Ia, b) have a pronounced anti-inflammatory and analgesic activity, less toxic than the comparison drug voltaren. Therefore, the claimed compounds (Ia, b) can find application in medical practice as anti-inflammatory and analgesic drugs.
Claims (2)
обладающие противовоспалительной и анальгетической активностью.1. N- (1,3-Thiazol-2-yl) amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexanoic acid of the general formula Ia, b
possessing anti-inflammatory and analgesic activity.
отличающийся тем, что 5-трет-бутил-3-дифенилгидразона-2,3-дигидро-2-фуранона подвергают взаимодействию с 2-аминотиазолом или 2-амино-4-фенилтиазолом при нагревании в среде абсолютного толуола. 2. The method of obtaining N- (1,3-thiazol-2-yl) amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexanoic acid of the general formula Ia, b
characterized in that 5-tert-butyl-3-diphenylhydrazone-2,3-dihydro-2-furanone is reacted with 2-aminothiazole or 2-amino-4-phenylthiazole when heated in absolute toluene.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007128279/04A RU2345072C1 (en) | 2007-07-23 | 2007-07-23 | N-(1,3-tiazol-2-yl)amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexane acid, demonstrating anti-inflammatory and analgetic activity and method of obtaining |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007128279/04A RU2345072C1 (en) | 2007-07-23 | 2007-07-23 | N-(1,3-tiazol-2-yl)amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexane acid, demonstrating anti-inflammatory and analgetic activity and method of obtaining |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2345072C1 true RU2345072C1 (en) | 2009-01-27 |
Family
ID=40544193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007128279/04A RU2345072C1 (en) | 2007-07-23 | 2007-07-23 | N-(1,3-tiazol-2-yl)amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexane acid, demonstrating anti-inflammatory and analgetic activity and method of obtaining |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2345072C1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2783158C2 (en) * | 2021-04-05 | 2022-11-09 | Федеральное государственное бюджетное образовательное учреждение высшего образования «Пермская государственная фармацевтическая академия» Министерства здравоохранения Российской Федерации | Substituted hydrazides of 2-diarylmethylene hydrazone-5,5-dimethyl-4-oxohexanoic acids exhibiting anti-inflammatory activity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2074568A1 (en) * | 1991-07-24 | 1993-01-25 | Rupert Strasser | Dimethyl acetoacetamides, process for their preparation and pharmaceuticals |
| FR2865207A1 (en) * | 2004-01-16 | 2005-07-22 | Sanofi Synthelabo | New N-thiazolyl-amides, useful for treating e.g. dementia and neurodegenerative diseases, are inhibitors of the formation of beta-amyloid peptide A4 |
-
2007
- 2007-07-23 RU RU2007128279/04A patent/RU2345072C1/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2074568A1 (en) * | 1991-07-24 | 1993-01-25 | Rupert Strasser | Dimethyl acetoacetamides, process for their preparation and pharmaceuticals |
| FR2865207A1 (en) * | 2004-01-16 | 2005-07-22 | Sanofi Synthelabo | New N-thiazolyl-amides, useful for treating e.g. dementia and neurodegenerative diseases, are inhibitors of the formation of beta-amyloid peptide A4 |
Non-Patent Citations (1)
| Title |
|---|
| Березина Е.С. и др. Амиды и гидразиды ацилпировиноградных кислот VIII. Синтез амидов пивалоилпировиноградной кислоты и их взаимодействие с бензиламином и ариламинами. Журнал органической химии, 2001, т.37, вып.4, с.574-581. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2783158C2 (en) * | 2021-04-05 | 2022-11-09 | Федеральное государственное бюджетное образовательное учреждение высшего образования «Пермская государственная фармацевтическая академия» Министерства здравоохранения Российской Федерации | Substituted hydrazides of 2-diarylmethylene hydrazone-5,5-dimethyl-4-oxohexanoic acids exhibiting anti-inflammatory activity |
| RU2810070C1 (en) * | 2023-03-30 | 2023-12-21 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | Ethyl ether 2-amino-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-5-(2-(4-ethylphenyl)-2-oxoethylidene)-4-oxo- 4,5-dihydro-1h-pyrrol-3-carboxylic acid with analgesic activity |
| RU2829965C1 (en) * | 2024-04-15 | 2024-11-11 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | 4-(3,4-dimethoxyphenyl)-2-[2-(4-methylbenzoyl)hydrazono]-4-oxo-n-[4-(n-thiazol-2-yl)sulfamoyl)phenyl]butanamide, having analgesic activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2389724C1 (en) | 4-(4-methylphenyl)-4-oxo-2-[3-(ethoxycarbonyl-4,5-r2,r1-thiophen-2-ylamino]but-2-enoic acid, having anti-inflammatory and analgesic activity | |
| RU2345072C1 (en) | N-(1,3-tiazol-2-yl)amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-dioxohexane acid, demonstrating anti-inflammatory and analgetic activity and method of obtaining | |
| RU2503671C1 (en) | (Z)-2-[(3-CARBAMOYL-4,5,6,7-TETRAHYDROBENZO[b]THIEN-2-YL)AMINO]-4-(4-R-PHENYL)-4-OXOBUT-2-ENOIC ACIDS, HAVING ANALGESIC ACTIVITY | |
| RU2364592C1 (en) | N-[2-(5-ethyl-1,3,4-thiadiazolyl)]amide of 2-(2-hydroxyphenyl)-2-oxoethane acid, possessing anti-inflammatory and analgesic activity | |
| RU2396263C2 (en) | Bis{3-phenyl-1-[2-(5-methyl-1,3,4-thiadiazolyl)]carboxamido-1,3-propanedionato}manganese having anti-inflammatory and analgesic actvity | |
| RU2501795C1 (en) | N-R-AMIDES OF (Z)-2[(3-ETHOXYCARBONYL)-4,5,6,7-TETRAHYDROBENZO [b]THIEN-2-YL)AMINO]-4-PHENYL-4-OXOBUT-2-ENOIC ACIDS, HAVING ANALGESIC ACTIVITY | |
| RU2631649C1 (en) | ETHYL ETHER OF 2-(((Z)-AMINO((Z)-2,4-DIOXO-5-(2-OXO-2-PHENYLETHYLIDENE)PIRROLIDINE-3-YLIDEN)METHYL)AMINO)-4,5,6,7-TETRAHYDROBENZO[b]THIOPHENCARBOXYLIC ACID WITH ANALGETIC ACTIVITY | |
| RU2809054C1 (en) | USE OF AN ANALGETIC DRUG BASED ON 2-((6-(4-METHOXYPHENYL)-2-METHYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4(1H)-YLIDENE)AMINO)-4,5,6,7- AMIDE TETRAHYDROBENZO[b]THIOPHENE-3-CARBOXYLIC ACID | |
| RU2779193C1 (en) | APPLICATION OF 2-[(1,4-DIOXO-1-R1-4-(4-METHOXYPHENYL)BUT-2-ENE-2-YL)AMINO]-4,5,6,7-TETRAHYDROBENZO[b]THIOPHENE-3-CARBOXYLIC ACID AMIDES AS AN ANALGESIC MEDICINAL PRODUCT | |
| RU2798429C1 (en) | 2-CYANO-4-[1,6-DIOXO-6-(4-METHYLPHENYL)-1-ETOXY-4-(3-CYANO-4,5,6,7-TETRAHYDROBENZO[b]THIOPHEN-2-IL)AMINO]HEXA-2,4-DIEN-3-OLATE POTASSIUM WITH ANALGESIC ACTIVITY | |
| RU2776070C1 (en) | APPLICATION OF AN ANALGESIC AGENT BASED ON POTASSIUM 1,6-DIOXO-6-(4-CHLOROPHENYL)-2-CYANO-1-ETHOXY-4-[((3-ETHOXYCARBONYL)-4,5,6,7-TETRAHYDROBENZO[b]THIOPHENE-2-YL)AMINO]HEXA-2,4-DIENE-3-OLATE | |
| RU2771031C1 (en) | Ethyl ether (5 e)-2-amino-5-[2-(4-methylphenyl)-2-hydroxyethylidene]-1-(3-nitrophenyl)-4-oxo-1h-4,5-dihydropyrrol-3-carboxylic acid, with antinociceptive activity | |
| RU2831124C1 (en) | SODIUM 1-AMINO-1,6-DIOXO-6-(P-TOLYL)-2-CYANO-4-((3-CYANO-4,5,6,7-TETRAHYDROBENZO[b]THIOPHEN-2-YL)AMINO)HEXA-2,4-DIENE-3-OLATE, HAVING ANALGESIC ACTIVITY | |
| RU2798427C1 (en) | 2-(2-(4-nitrobenzoyl)hydrasono)-4-oxo-4-(4-methylphenyl)butanoic acid octyl ether with analgesic activity | |
| RU2485112C1 (en) | 4-(4-bromophenyl)-4-oxo-2-{[3-ethoxycarbonyl)-4,5-dimethylthien-2-yl]amino}-2-butenoic acid, having anti-inflammatory and analgesic activity | |
| RU2798430C1 (en) | 1-phenylethyl ether of 2-(2-(4-nitrobenzoyl)hydrazono)-4-oxo-4-(4-methylphenyl)butanoic acid with analgesic activity | |
| RU2810078C1 (en) | POTASSIUM 2-(4-BROMOPHENYL)-6-OXO-4-(PHENYLIMINO)-1,6-CYANO-1-((4-CYANO-3-TETRAHYDROBENZO[b]THIOPHEN-4,5,6,7-YL)AMINO)-2-ETOXYHEXA-2,4-DIENE-3-OLATE WITH ANALGESIC ACTIVITY | |
| RU2810070C1 (en) | Ethyl ether 2-amino-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-5-(2-(4-ethylphenyl)-2-oxoethylidene)-4-oxo- 4,5-dihydro-1h-pyrrol-3-carboxylic acid with analgesic activity | |
| RU2810252C1 (en) | 5-AMINO-1-(2-OXO-2-PHENYLETHYLIDENE)-3-(PYRROLIDINE-1-CARBONYL)-6,7,8,9-TETRAHYDROBENZO[4,5]THIENO[3,2-e]PYRROLO[1,2-a]PYRIMIDIN-2(1H)-ONE, WHICH HAS ANALGESIC ACTIVITY | |
| RU2808997C1 (en) | OBTAINING 6-(4-BROMOPHENYL)-6-OXO-1-(PHENYLIMINO)-2-CYANO-4-((3-CYANO-4,5,6,7-TETRAHYDROBENZO[b]THIOPHEN-2-YL)AMINO)-1-ETOXYHEXA-2,4-DIENE-3-OLATE POTASSIUM WITH ANALGESIC ACTIVITY | |
| RU2785784C1 (en) | APPLICATION OF 4-(4-METHOXYPHENYL)-4-OXO-2-[(3-(CYANO)-4,5,6,7-TETRAHYDROBENZO[b]THIOPHEN-2-yl)AMINO]BUT-2-ENOIC ACID AS AN ANALGESIC DRUG | |
| RU2808995C1 (en) | OBTAINING 2-((6-(2-METHOXYPHENYL)-3-OXO-2-ETHYL-2,3-DIHYDROPYRIDAZIN-4-YL)AMINO)-4,5,6,7-TETRAHYDROBENZO[b]THIOPHENE-3-CARBONITRILE WITH ANALGESIC ACTIVITY | |
| RU2348613C2 (en) | 2-(1,2-diphenyl-2-oxoethylidenehydrazino)-4-(4-methoxyphenyl)-4-oxobut-2-ene acid with anti-inflammatory and analgesic effect | |
| RU2798425C1 (en) | 4-oxo-n-(furan-2-ylmethyl)-4-(4-chlorophenyl)-2-((3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)amino)but-2-enamide with analgesic activity | |
| RU2810072C1 (en) | 4-(4-METHOXYPHENYL)-4-OXO-N-PHENYL-2-((3-CYANO-4,5,6,7-TETRAHYDROBENZO[b]THIOPHEN-2-YL)AMINO)BUT-2-ENAMIDE WITH ANALGESIC ACTIVITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090724 |